Regulatory · 2026-07-30

The proposal that would end bulk-compounded GLP-1s

Evidence-sourced

Written and fact-checked to our published editorial standards.Last updated 2026-08-11. Every clinical claim on this page is sourced to a named primary authority, listed at the foot of the page — see how we research, source, and correct our work.

Direct answer

What you need to know

Evidence strength: Strong

Comments closed on 30 July 2026, and a decision is pending as we write. The FDA has proposed leaving semaglutide, tirzepatide and liraglutide off the 503B bulks list, saying it did not identify sufficient evidence of a clinical need for outsourcing facilities to compound them. If finalised, that removes the last general route for compounding these drugs at scale — the shortage-based route already closed in 2025.

Key takeaways

Proposed 30 April 2026, published in the Federal Register 1 May 2026.
The comment deadline was extended from 30 June to 30 July 2026.
Nothing has been finalised. Compounded products remain available while it is pending.
This affects 503B outsourcing facilities. Patient-specific 503A compounding is a separate provision.

Important limitation: We cannot tell you what the FDA will decide, when, or what any individual provider will do in response. What we can do is record the dates accurately and say plainly that the position is mid-change.

Next action: If you are using or considering a compounded product, the thing to understand first is what “compounded” actually means and what has and has not been reviewed — that is on compounded semaglutide. Ask your provider directly what happens to your supply if the proposal is finalised.

Primary sources: Federal Register, 91 FR 23431 (document 2026-08552), Federal Register (document 2026-12937)

General education, not medical or legal advice. Nothing here is a recommendation to start, stop, or change a medication.

What was proposed

Outsourcing facilities registered under section 503B generally cannot compound a drug from a bulk substance unless that substance is on the 503B bulks list, or the drug is on the FDA’s shortage list at the time. The bulks list is the mechanism that permits compounding at scale rather than one prescription at a time.

On 30 April 2026 the FDA announced it was proposing not to add semaglutide, tirzepatide or liraglutide to that list. The Federal Register notice appeared the following day. The agency’s stated basis was that it reviewed the nominations it received and did not identify sufficient evidence of a clinical need for outsourcing facilities to compound these substances.

The timeline, with the dates that matter

Every date below is from the Federal Register or FDA’s own announcement, cited at the foot of this page.
21 February 2025	FDA declares the semaglutide injection shortage resolved.
22 April 2025	Enforcement discretion ends for 503A pharmacies compounding products that are essentially a copy of the approved drug.
22 May 2025	The same deadline for 503B outsourcing facilities.
30 April 2026	FDA announces the proposal to leave all three molecules off the bulks list.
1 May 2026	Federal Register notice published. Comments due 30 June.
26 June 2026	Comment period extended to 30 July 2026, following a request for more time.
30 July 2026	Comments close. Decision pending.

The shortage route closed in 2025. This proposal would close the other one. Neither ends compounding — both narrow who can do it, and at what scale.

What it does not mean

Nothing has been decided. A proposal with a closed comment period is not a rule. Compounded products remain available while it is pending.
It is not a ban on compounding. Section 503A — a pharmacy filling one patient-specific prescription — is a different provision and is not what this proposal addresses.
It is not a safety finding about any particular product. The stated basis is the absence of evidence of clinical need for bulk compounding, which is a different question from whether a given preparation is safe.

What we got wrong

Our provider directory stated that the comment period closed on 29 June 2026. That was wrong twice over: the original deadline was 30 June, and it was then extended to 30 July. The directory has been corrected and the change is logged on our corrections page, which until today was empty.

It is the kind of error that matters more than it looks. A reader deciding whether to start a compounded product this month would have been told the window had shut a month earlier than it did.

Sources

Each source below supports specific statements on this page. We cite the strongest available authority and verify against the current version before publishing.

List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic ActFederal Register, 91 FR 23431 (document 2026-08552)Supports: The proposal itself, published 1 May 2026, and FDA's finding that it did not identify sufficient evidence of clinical need to include semaglutide, tirzepatide or liraglutide on the 503B bulks list.
List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B; Extension of Comment PeriodFederal Register (document 2026-12937)Supports: The extension published 26 June 2026, which moved the comment deadline to 30 July 2026 — the date this page records, and the one we previously got wrong.
FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks ListU.S. Food & Drug AdministrationSupports: FDA's own announcement of the proposal, dated 30 April 2026.
Drug approvals, labeling and safety communicationsU.S. Food & Drug AdministrationSupports: The 503A and 503B compounding provisions, and the separate shortage-based enforcement dates that ended in 2025.

This page is general education, not medical advice. Talk to your own healthcare provider about your situation before starting, stopping, or changing any medication.